secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628908-24-000089
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q2 revenue $647M (+38% YoY); net loss narrows to $6.4M; Adj. EBITDA $52M; narrows FY outlook
--------------------------------------------------------------------------------

- Revenue $647.1M, up 37.9% YoY from $469.1M; net loss $(6.4)M vs $(41.4)M loss in Q2 2023.
- Adjusted EBITDA $52.0M (8.0% margin) vs $47.4M (10.1% margin) in prior year.
- Narrows full-year 2024 revenue outlook and updates Adjusted EBITDA guidance; reaffirms $300M exit run rate target.
- Performance Suite average lives grew to 6,901 from 3,810 YoY; signed new oncology and specialty deals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890824000089/0001628908-24-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890824000089/evh-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628908-24-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer